A brief communication reports an association between GLP-1 receptor agonist use and improved survival among patients undergoing surgery for traumatic brain injury, drawing on clinical data from multiple sites. The observation adds to a growing—though still exploratory—body of lab evidence suggesting incretin signaling could modulate neuroinflammation and injury cascades after TBI.